RT Journal Article SR Electronic T1 Genetic variants in the SHISA6 gene are associated with delayed cognitive impairment in two family datasets JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.02.21259940 DO 10.1101/2021.07.02.21259940 A1 Ramos, Jairo A1 Caywood, Laura J. A1 Prough, Michael B. A1 Clouse, Jason E. A1 Herington, Sharlene D. A1 Slifer, Susan H. A1 Fuzzell, M. Denise A1 Fuzzell, Sarada L. A1 Hochstetler, Sherri D. A1 Miskimen, Kristy L. A1 Main, Leighanne R. A1 Osterman, Michael D. A1 Laframboise, Owen A1 Zaman, Andrew F. A1 Whitehead, Patrice L. A1 Adams, Larry D. A1 Laux, Renee A. A1 Song, Yeunjoo E. A1 Foroud, Tatiana M. A1 Mayeux, Richard P. A1 George-Hyslop, Peter St. A1 Ogrocki, Paula K. A1 Lerner, Alan J. A1 Vance, Jeffery M. A1 Cuccaro, Michael L. A1 Haines, Jonathan L. A1 Pericak-Vance, Margaret A. A1 Scott, William K. YR 2021 UL http://medrxiv.org/content/early/2021/07/07/2021.07.02.21259940.abstract AB Background Studies of cognitive impairment (CI) in Amish communities have identified sibships containing multiple CI and cognitively unimpaired (CU; unaffected after age 75) individuals. We hypothesize that these CU individuals may carry protective alleles delaying age at onset (AAO) of CI, preserving cognition in older age despite increased genetic risk. As well, the genetic and cultural isolation in the Amish since the early 1800s may have reduced the complexity of the genetic architecture of CI, increasing the power to detect protective alleles in this population. With this in mind we conducted a genome-wide study (GWAS) to identify loci associated with AAO of CI in a sample of Amish adults over age 75.Methods 1,522 individuals aged 43-99 (mean age 73.1, 42% men) screened at least once for CI using the Modified Mini-Mental State exam (3MS) were genotyped using Illumina chipsets. Genotypes were imputed for 7,815,951 single nucleotide variants (SNV) with minor allele frequency (MAF) > 1%. The outcome studied was age, defined as 1) age at the first 3MS result indicating impairment (AAO; 3MS <87; 362 CI individuals) or 2) age at last normal exam (3MS >=87, 1,160 CU individuals). Cox mixed-effects models examined association between age and each SNV, adjusting for sex and familial relationships. To replicate genome-wide significant findings, SNVs in a 1 Megabase region centered on the peak SNV were examined for association with age using these same methods in the NIA-LOAD family study dataset (1,785 AD cases, 1,565 unaffected controls, mean age 73.5.Results Three SNV were significantly associated (p<5 x 10-8) with AAO in the Amish, on chromosomes 6 (rs14538074; HR=3.35), 9 (rs534551495; HR=2.82), and 17 (rs146729640; Hazard Ratio (HR)=6.38). Each region found the common allele associated with later AAO. Replication analysis detected association at rs146729640, with nominal statistical significance (HR=1.49, p=0.02).Conclusions The replicated genome-wide significant association with AAO on chromosome 17 suggest this may be novel locus associated with delayed onset of AD. The associated SNP is located in the SHISA6 gene, which is involved in post-synaptic transmission in the hippocampus and is a biologically plausible candidate gene for AD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by National Institutes of Health / National Institute of Aging, grant 1RF1AG058066 (to Jonathan L. Haines, Margaret Pericak-Vance, and William K. Scott) and grant U24 AG056270 (to Tatiana M. Foroud, Alison M. Goate and Richard P. Mayeux).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Subjects approvals obtained from IRB at Case Western Reserve University and University of Miami.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenotype and case/control phenotype data for the NIA/LOAD dataset is deposited in the NIAGADS portal. The genotype and phenotype data from the Amish discovery sample will be deposited in this portal upon publication. http://www.niagads.org